Balance Sheet and Combined Deficit Components (Tables)

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

	Successor		Predecessor
	June 30, 2021		December 31, 2020
D&O Insurance	$	10,234	$	9
Research and development costs	3,941		992
Value added tax receivable	1,365		298
Other	444		6
	$	15,984	$	1,305

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	Successor		Predecessor
	June 30, 2021		December 31, 2020
D&O Insurance	$	8,367	$	—
Research and development expenses	3,984		1,001
Professional fees	3,271		37
Personnel related expenses	907		—
Other	395		9
	$	16,924	$	1,047

Schedule of Combined Deficit

Combined deficit of the Centessa Predecessor Group at December 31, 2020 consisted of the following (in thousands):

	Predecessor
	December 31, 2020
Morphogen-IX deficit
Ordinary shares	$	13
Additional paid-in capital	364
Accumulated other comprehensive income	629
Accumulated deficit	(9,225)
Total Morphogen-IX deficit	$	(8,219)
Z Factor deficit
Ordinary shares	$	12
Additional paid-in capital	461
Accumulated other comprehensive income	139
Accumulated deficit	(8,568)
Total Z Factor deficit	$	(7,956)
LockBody deficit
Ordinary shares	$	—
Additional paid-in capital	—
Accumulated other comprehensive income (loss)	(196)
Accumulated deficit	(6,052)
Total LockBody deficit	$	(6,248)
Total combined deficit	$	(22,423)